Altimmune (NASDAQ:ALT) Stock Rating Lowered by Wall Street Zen

Altimmune (NASDAQ:ALT) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities analysts also recently issued research reports about the stock. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Barclays assumed coverage on shares of Altimmune in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Thursday. Finally, Citizens Jmp decreased their price objective on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a report on Friday, November 7th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Altimmune has a consensus rating of “Hold” and a consensus target price of $16.60.

Altimmune Trading Up 0.9%

Shares of ALT stock opened at $3.54 on Friday. The company has a market capitalization of $399.43 million, a price-to-earnings ratio of -3.50 and a beta of 0.13. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average price of $4.48 and a 200 day moving average price of $4.29. Altimmune has a twelve month low of $2.90 and a twelve month high of $7.73.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 54.03% and a negative net margin of 214,860.98%. Research analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Activity at Altimmune

In related news, Director Jerome Benedict Durso bought 12,500 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were acquired at an average cost of $4.13 per share, with a total value of $51,625.00. Following the completion of the transaction, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Gill bought 12,500 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The stock was bought at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director owned 12,500 shares of the company’s stock, valued at $51,250. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 30,527 shares of company stock worth $125,278 over the last three months. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Altimmune

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in Altimmune by 13.4% in the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after acquiring an additional 228,995 shares during the last quarter. Brown Wealth Management LLC grew its position in Altimmune by 131.0% during the second quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock valued at $894,000 after acquiring an additional 131,059 shares during the period. Intech Investment Management LLC increased its stake in Altimmune by 102.9% during the second quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock worth $561,000 after acquiring an additional 73,482 shares during the last quarter. Jefferies Financial Group Inc. increased its stake in Altimmune by 40.0% during the second quarter. Jefferies Financial Group Inc. now owns 35,000 shares of the company’s stock worth $135,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its stake in Altimmune by 43.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 213,384 shares of the company’s stock worth $826,000 after acquiring an additional 64,175 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

More Altimmune News

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Company advanced pemvidutide development — management reiterated plans to initiate a Phase 3 MASH trial in 2026, pemvidutide received FDA Breakthrough Therapy designation for MASH, and RECLAIM Phase 2 topline data in AUD is expected in 3Q 2026. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Balance sheet strengthened — company reported about $274M in cash, cash equivalents and short-term investments at year-end and completed a $75M registered direct offering in January, supporting clinical programs and runway. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Company outlined a large, 1,800‑patient Phase III MASH design and signaled cash runway into 2028 as pemvidutide advances — this reduces near-term execution risk for the lead program. Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028
• Neutral Sentiment: B. Riley cut its price target from $18 to $13 but kept a Buy rating — the new target still implies meaningful upside vs. current levels, though it reduces analyst enthusiasm relative to prior coverage. Benzinga
• Neutral Sentiment: Earnings call and transcripts are available for review — useful for investors who want management’s commentary on timelines, trial designs and cash runway. Altimmune Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short-interest notes appear to show anomalous/zero values in public data feeds and are not a reliable signal at this time.
• Negative Sentiment: Q4 earnings missed estimates — EPS of ($0.27) vs. consensus ($0.25) and immaterial GAAP revenue ($0.03M); very large negative margins and negative ROE highlight ongoing R&D spending and lack of commercial revenue. Altimmune stock edges down on fourth quarter earnings miss

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.